The Trinity Biomedical Sciences Institute is a state-of-the-
airmid healthgroup ltd , which is co-founded by a doctor from Trinity College, is based in the Trinity Enterprise Park and will have strong technology transfer and commercialisation links with the Trinity Biomedical Institute. As well as continuing its existing research ties with the University campus particularly in the region of microbiology.
Built around the areas of immunology, cancer and medical devices and linked directly to both medical education and industrial collaboration, the Institute will contribute to the improvement of the physical health of society on a global stage.
Ireland is home to nine of the top ten global companies in this sector and approximately 47,000 people are employed in indigenous and multinational companies in this area. Irish research in this domain is among the world’s best, with Trinity College Dublin researchers to the forefront in key areas such as immunology and infection.
The new facility will bring over 700 researchers together in one building with the common goal of addressing major challenges in health and disease through leading edge scientific research.
“Trinity researchers have led world-class research in biomedical sciences from developing the nicotine patch to identifying new genes for childhood eczema and increasing our understanding of major diseases such as Alzheimer’s disease, cancer and arthritis.” said TCD Dean of Research, Dr David Lloyd. “The University’s international rankings show its outputs are amongst the best in the world in immunology, neuroscience, microbiology and many other key fields”.
“This is a wonderful day for Trinity College, my Alma Mater, with the opening of this €131 million biomedical Institute” said Dr McKeon airmid healthgroup ltd Director. “We have strong links with the college both with the graduate school of business and in life science research. The Trinity Enterprise Campus, where our laboratories are, is in the next block to the Institute so we will deepen our collaboration and research links with some world class studies already at advanced planning”.
The new facility will consolidate and integrate pre-clinical bioscience research from across five schools: Medicine; Biochemistry and Immunology; Pharmacy and Pharmaceutical Science; Chemistry and Engineering.